Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
2.8
Journals
CIMB
Special Issues
The Significance of Transcription Factors, miRNAs, and lncRNAs in Anticancer...
cimb-logo
Submit to Special Issue Submit Abstract to Special Issue Review for CIMB Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

The Significance of Transcription Factors, miRNAs, and lncRNAs in Anticancer Drug Development, 2nd Edition

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 852

Special Issue Editors

Prof. Dr. Ru Chih C. Huang

E-Mail Website
Guest Editor
1. Department of Biology, Zanvyl Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218-2685, USA
2. National Academy of Inventors, Tampa, FL 33612, USA
3. Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 11529, Taiwan
Interests: chromatin structure and function; tetra-O-methyl nordihydroguaiaretic acid (M4N, terameprocol); oncogenic development in humans; chemotherapeutic drug treatments; viral replication; gene functions
Special Issues, Collections and Topics in MDPI journals
Dr. Kotohiko Kimura

E-Mail Website
Guest Editor
Department of Biology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218-2685, USA
Interests: anticancer drug; combination drug treatment; transcription factor; gene regulation; alternative splicing; cancer metabolism; mitochondria; apoptosis and hypoxia
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent progress in system biology has shown that several specific factors are part of a network functioning as a master regulator of cancer. These factors are usually transcription factors, microRNAs (miRNAs), and long non-coding RNAs (lncRNAs) in control of the expression of various genes playing important roles in the regulation of cancer development. This suggests that there may be a way to induce unfavorable effects in cancer development and progression by modulating the activity and/or expression of these specific factors. In this Special Issue, we will focus on studies that investigate the roles and mechanisms of transcription factors, miRNAs, and lncRNAs in the regulation of the expression of cancer-related genes and/or proteins and search for potential drugs that cause adverse effects against cancer by modulating the activity of these specific factors, thus manipulating the activity and/or expression of various cancer-related genes and/or proteins. In other words, this Special Issue focuses on the effort to discover potentially effective anticancer drugs by targeting transcription factors, miRNAs, and lncRNAs that function as master regulators of cancer.

You can read the publications in the first volume of our Special Issue at https://www.mdpi.com/journal/cimb/special_issues/X459J1D74V.

Prof. Dr. Ru Chih C. Huang
Dr. Kotohiko Kimura
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • transcription factors
  • microRNAs (miRNAs)
  • long non-coding RNAs (lncRNAs)
  • anticancer drugs
  • cancer
  • coactivators

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

23 pages, 2076 KiB  
Article
Regulatory Roles of miR-155-5p, miR-21-5p, miR-93-5p, and miR-140-5p in Breast Cancer Progression
by Mai S. Degheidy, Amany A. Abou-Elalla, Mahmoud M. Kamel, Shaimaa Abdel-Ghany, Borros Arneth and Hussein Sabit
Curr. Issues Mol. Biol. 2025, 47(5), 377; https://doi.org/10.3390/cimb47050377 - 20 May 2025
Viewed by 358
Abstract
Breast cancer (BC) remains the leading cause of cancer-related morbidity and mortality worldwide, necessitating innovative approaches to improve diagnosis, prognosis, and treatment. This case-control study, aimed to evaluate the expression profiles of specific microRNAs (miRNAs)—miR-155-5p, miR-21-5p, miR-93-5p, and miR-140-5p—in 50 female BC patients [...] Read more.
Breast cancer (BC) remains the leading cause of cancer-related morbidity and mortality worldwide, necessitating innovative approaches to improve diagnosis, prognosis, and treatment. This case-control study, aimed to evaluate the expression profiles of specific microRNAs (miRNAs)—miR-155-5p, miR-21-5p, miR-93-5p, and miR-140-5p—in 50 female BC patients treated with paclitaxel (PTX) compared to 50 healthy controls. miRNA expression was analyzed using qPCR. The study revealed significant up regulation of these miRNAs in BC patients, with miR-155-5p and miR-21-5p demonstrating the highest diagnostic accuracy (AUC = 0.890 and 0.863, respectively). These miRNAs are implicated in key oncogenic processes, including tumor growth, angiogenesis, metastasis, and chemoresistance, highlighting their potential as non-invasive biomarkers for BC diagnosis and prognosis. Additionally, the study identified significant differences in demographic and biochemical parameters between BC patients and controls, such as lower hemoglobin and RBC counts in patients, indicative of cancer-related anemia, and elevated AST levels. The findings underscore the importance of miRNAs in BC biology and their potential to guide personalized therapeutic strategies. Validation in larger cohorts is recommending and exploring miRNA-based interventions to improve patient outcomes and overcome chemoresistance in BC. Full article
(This article belongs to the Special Issue The Significance of Transcription Factors, miRNAs, and lncRNAs in Anticancer Drug Development, 2nd Edition)
►▼ Show Figures

Figure 1

19 pages, 2190 KiB  
Article
Evaluation of the Expression of IDO and PTEN in Human Kidney Cancer
by Gábor Kónya, Zsuzsanna Szabó, Nikoletta Dobos, József Király, Krisztián Szegedi, Anna Vass, Ákos Steli, Csaba Szász, Balázs Dezső, Barbara Zsebik and Gábor Halmos
Curr. Issues Mol. Biol. 2025, 47(5), 359; https://doi.org/10.3390/cimb47050359 - 13 May 2025
Viewed by 377
Abstract
Immunotherapy has become one of the primary forms of cancer treatment. The inhibition of immune checkpoint molecules, including indoleamine 2,3-dioxygenase (IDO), is a promising approach for immunotherapy. Phosphatase and tensin homolog (PTEN) is well known as a tumor suppressor that antagonizes oncogenic signaling [...] Read more.
Immunotherapy has become one of the primary forms of cancer treatment. The inhibition of immune checkpoint molecules, including indoleamine 2,3-dioxygenase (IDO), is a promising approach for immunotherapy. Phosphatase and tensin homolog (PTEN) is well known as a tumor suppressor that antagonizes oncogenic signaling molecules/pathways and plays a key role in the prognosis and (immuno)therapy of the disease. In this study, twenty healthy and tumorous renal tissue pairs were investigated, and the mRNA (RT-qPCR) and protein (Western blot) expression of IDO and PTEN were analyzed. In two cancer cell lines (CAKI-2; A-498), the protein of IDO and PTEN was measured followed by IDO induction with interferon alpha-2 (IFN-α2). According to our results, a significantly higher mRNA expression of IDO and PTEN was found in tumorous tissues compared to the adjacent healthy kidney specimens. The mRNA expression of IDO and PTEN showed a positive correlation in 80% of the sample pairs. Western blot results confirmed the protein expression of both IDO and PTEN. In the cell lines, immunocytochemistry showed that IDO is inducible with IFN-α2. In summary, our results suggest that IDO expression may play a role in the development of renal cancer, and IDO as well as PTEN might be potential biomarkers for patients with RCC. Full article
(This article belongs to the Special Issue The Significance of Transcription Factors, miRNAs, and lncRNAs in Anticancer Drug Development, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop